Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding Study


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05252598

Organisation Name: Optimi Health Corporation

Overal Status: Not yet recruiting

Start Date: April 2022

Last Update: February 23, 2022

Lead Sponsor: Optimi Health Corporation

Brief Summary: This study is seeking to find the optimal microdose or low dose of psilocybin (magic mushrooms) that provides general enhancements to mood, memory, sleep, and other measures of general well-being without any hallucinogenic effects.

Conditions:
  • Mood Disturbance
  • Mood Change
  • Sleep Disturbance
  • Drug Effect
  • Psychedelic Experiences
  • Health, Subjective
  • Psilocin Toxicity
  • Psilocybin Toxicity
  • Psilocybin Causing Adverse Effects in Therapeutic Use
  • Anxiety


Total execution time in seconds: 0.19650888442993